Veru Inc. (VERU) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of ...

Fintel reports that on May 14, 2024, B. Riley Securities initiated coverage of Veru (NasdaqCM:VERU) with a Buy recommendation. As of May 8, 2024, the average one-year price target for Veru is 3.06.

MIAMI, FL, July 22, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and ...

Veru Inc. (VERU) is a great speculative biotech play to look into, despite a rejection by the FDA of the Emergency Use Authorization (EUA) of Sabizabulin for the treatment of patients with moderate to ...

SAN DIEGO--(BUSINESS WIRE)--Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Veru Inc. (NASDAQ: VERU) common stock between May 11, 2022 and November 9, 2022, both dates ...

NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Veru Inc. (NASDAQ: VERU) on behalf of long-term ...

MIAMI, FL, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic ...

Veru Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, ladies and gentlemen, and welcome to the Veru Inc.

MIAMI, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company developing novel medicines for the prostate cancer continuum of care and urology ...

MIAMI, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer, ...